(Hypertension. 2001;37:1458.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Departments of Medicine (D.N.C., D.B.S., R.P.L.) and Genetics (C.N.-W., A.F., K.F., L.B., R.P.L.), Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Conn; and the National Institutes of Health (J.R.G.), Bethesda, Md.
Correspondence to Dr Richard P. Lifton, Howard Hughes Medical Institute, Boyer Center for Molecular Medicine, 295 Congress Ave, New Haven, CT 06510. E-mail richard.lifton{at}yale.edu
| Abstract |
|---|
|
|
|---|
Key Words: blood pressure sodium, dietary hypokalemia human diuretics genetics
| Introduction |
|---|
|
|
|---|
Studies of rare inherited forms of hypertension have begun to provide insight into this issue. In recent years, the molecular basis of glucocorticoid-remediable aldosteronism, Liddles syndrome, and the syndrome of apparent mineralocorticoid excess have been defined.2 All result from mutations that lead to increased renal reabsorption of salt by the epithelial Na+ channel of the distal nephron. This initiates a rise in blood pressure by the expansion of plasma volume and the consequent increased cardiac output. The cosegregation of hypertension with these mutations has demonstrated a causal link between them.2
These observations raise the question of whether mutations that diminish renal salt reabsorption have the opposite effect, ie, lowering blood pressure. Patients with Bartters and Gitelmans syndromes have salt wasting with hypokalemic alkalosis but, in contrast to the above disorders, remain free of hypertension, with so-called normal blood pressure.3 4 5 These observations raise the question of whether the normal blood pressure in these syndromes actually reflects diminished blood pressure resulting from reduced salt balance. Studies to test this possibility have been difficult to perform for several reasons: these disorders are rare autosomal recessive traits, making the investigation of many individuals under a uniform protocol problematic; second, there has been marked clinical variation among patients with hypokalemic alkalosis, raising the question of how to define distinct disease entities within this group. Third, for rare disorders with affected subjects of diverse ethnic and geographic backgrounds, identifying appropriate control populations for comparison has proved difficult.
This situation has changed with the recent demonstration of the molecular basis of Gitelmans and Bartters syndromes. Bartters syndrome is caused by mutation in any of 3 genes involved in salt reabsorption in the thick ascending limb of Henle.6 These patients are typically diagnosed in the neonatal period with severe intravascular volume depletion. In contrast, Gitelmans syndrome is caused by loss of function mutations in the Na-Cl cotransporter of the distal convoluted tubule (NCCT); a wide range of mutations causing disease have been identified.6 7 Patients with Gitelmans syndrome typically have a more benign clinical course, presenting with neuromuscular signs and symptoms in adolescence or adulthood; clinical signs of volume depletion are typically not apparent.3 6 In both disorders, the renal salt wasting activates the renin-angiotensin system, increasing Na+ reabsorption via the epithelial Na+ channel in the distal nephron. This provides the electrical gradient for increased secretion of K+ and H+, accounting for the hypokalemic alkalosis seen in affected patients. In addition, patients with Gitelmans syndrome typically have hypomagnesemia and hypocalciuria, in contrast to the normal serum Mg2+ levels and hypercalciuria typically seen in Bartters syndrome.3 4 6 7 It is important to point out that these effects of NCCT mutations have been identified only in patients presenting with these biochemical abnormalities, leaving open the possibility of ascertainment bias. Thus, although all patients with these clinical features of Gitelmans syndrome appear to have NCCT mutations, it has not been possible until now to determine the penetrance of the various clinical features resulting from NCCT mutations.
We have identified an Amish kindred with Gitelmans syndrome spanning 10 generations with many consanguineous loops; the ancestry of this kindred can be traced to a common pair of founders in the 18th century. Identification of the mutations underlying the disease in this kindred affords the opportunity to unambiguously follow the inheritance of mutant NCCT alleles and to then determine the impact of these alleles on biochemical features and blood pressure. This within-family study design provides an ideal control population, substantially eliminating the effects of differences in genetic backgrounds of cases and controls and permitting the assessment of clinical features free of ascertainment bias.
| Methods |
|---|
|
|
|---|
Blood pressure was measured in a standardized fashion. All blood pressures were measured by a single physician (D.N.C.). Three oscillometric blood pressure readings were measured at 5-minute intervals, by using the left arm of the patient, who was seated. The first reading was discarded, and the average of the second and third readings was used in data analysis. Hypertension was defined as a blood pressure >140/90 or the use of antihypertensive medications. Valid measurements were obtained in 194 subjects. Three young children could not cooperate for valid measurement. Two additional patients were excluded from analysis: 1 patient for chronic steroid use for multiple sclerosis and 1 patient for diltiazem use for cardiac dysrhythmia. Twenty-nine months after the initial blood pressure recordings, measurements were repeated in 63 subjects by the same methods. The repeated blood pressures, measured in a blinded fashion, showed a highly significant correlation with the initial readings (R=0.491 and P<0.001 for systolic blood pressure, R=0.459 and P<0.001 for diastolic blood pressure).
Biochemical measurements were all performed in the same laboratory by using standard procedures with subjects consuming their typical ad libitum diets. Serum K+ and Mg2+ levels were determined in all subjects. Measurements of serum bicarbonate (HCO3-) levels were performed in a subset of the subjects (n=39). In a subset of patients, 24-hour urinary Na+, urinary K+, and urinary Ca2+ levels were also measured (n=87, 87, and 125, respectively). These values are expressed as the millimolar ratios of urine electrolytes/creatinine (ie, urine Na+/creatinine, K+/creatinine, and Ca2+/creatinine).
Mutation Identification and Genetic
Testing
Genomic DNA was prepared from venous blood samples by
standard procedures.8
Mutations were sought by single-strand conformational polymorphism
of the NCCT gene as previously
described.7 Identified
variants were subjected to DNA sequencing according to standard
procedures.
The missense mutation identified in this kindred was genotyped in family members by polymerase chain reaction (PCR), followed by single-strand conformational polymorphism in kindred members. The deletion identified in this kindred was genotyped in family members by PCR. Deletion homozygotes were identified by the absence of NCCT PCR products, whereas exons from other genes in the same PCR reaction were successfully amplified, providing a positive control. These results were confirmed by Southern blotting, hybridizing probes from the deleted NCCT exons to genomic DNA of kindred members. Heterozygous carriers of the NCCT exon-1 to -7 deletion were identified by quantitative comparison of PCR amplification of exons 1 to 7 in family members with obligate heterozygotes and in normal control subjects. Inheritance of specific mutations was further confirmed by genotyping polymorphic markers tightly linked to NCCT. Importantly, all genotypic assignments were performed by individuals blinded to clinical data.
Statistical Analysis
The data are presented as mean±SEM. The
primary analysis compared the clinical characteristics of the 3
genotype groups by use of ANOVA for continuous variables
(age, serum K+,
Mg2+,
HCO3-, and urinary
Ca2+/creatinine) and
2 for categorical variables (gender
and the presence of hypertension), with a 2-tailed probability value.
Comparison of continuous variables between any 2 groups was
performed by use of the Student
t test. Univariate
linear regression analysis (Pearson correlation) was used to
examine the relationship between serum K+,
Mg2+,
HCO3-, and urinary
Ca2+/creatinine among affected
patients. This was also used to examine the correlation between
repeated blood pressure measurements (see above). Systolic and
diastolic blood pressure was analyzed for the
effect of genotype by using forward stepwise regression, with
age and gender considered a priori as covariates. Calculations
were performed by using SPSS 6.1 for Macintosh (SPSS Inc). A value of
P<0.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
GGC) in codon 642; this mutation substitutes
glycine for the normal arginine in the cytoplasmic C-terminus of the
encoded protein. This arginine residue lies in a 14amino acid segment
that is completely conserved among flounder, rat, and human
NCCTs,7 9 10
and the observed substitution is nonconservative, eliminating a
positive charge. This mutation is not a simple polymorphism in the
population, inasmuch as it was absent among 160 control chromosomes
studied. From these observations, as well as the cosegregation of this
mutation with the biochemical features of Gitelmans syndrome (see
below), we infer that this mutation leads to loss of
NCCT function. The other
allele in the index case contains a deletion that eliminates exons
1 to 7 of the gene. Seventeen individuals in the kindred were found to
be homozygous for this deletion by PCR, and the absence of this segment
of the gene in these individuals was confirmed by Southern blotting
(Figure 1). Because this deletion removes the start codon as
well as the first 5 transmembrane domains of the encoded protein, this
mutation is also inferred to result in a loss of function of
NCCT. Nine individuals were
compound heterozygotes with 1 copy of the deletion and 1 copy of the
missense mutation. There were no significant phenotypic differences
between the 2 classes of individuals homozygous for defective
NCCT alleles. No other
mutations in NCCT were
identified in this kindred.
|
Genotypes in the Extended
Kindred
The identification of these 2 mutations and marker
haplotypes segregating with them permitted unambiguous assessment of
the inheritance of these mutations through the extended kindred as
described in Methods. In sum, 199 members of this kindred were studied.
All members were classified as inheriting 0, 1, or 2 copies of
NCCT mutations
(Figure 2). This analysis revealed that 26 members
had inherited 2 defective copies of the gene (referred to as
genotypically affected subjects), 113 had inherited 1 defective copy
(heterozygotes), and 60 had inherited neither mutation (homozygous wild
types).
|
Among the 26 genotypically affected patients, there were 14 males and 12 females; among the heterozygous subjects, 52 males and 61 females; and among the wild-type subjects, 25 males and 35 females. The gender ratio of affected subjects was not significantly different from the expected 1/1 ratio, and the gender ratios among the 3 groups were not significantly different. Individuals inheriting 2 mutant alleles were older (mean age, 47.3 years) than their heterozygous and wild-type relatives (31.8 and 36.2 years, respectively; P=0.003), attributable to pedigree structure (Figure 2).
Biochemical Features of Members of K140
Heretofore, identification of patients with Gitelmans
syndrome has relied on the identification of abnormal serum
chemistries, potentially introducing ascertainment bias in assessment
of the severity of disease; ie, previously, one would not have been
able to identify patients inheriting these mutations who had no
biochemical abnormalities. Consequently, identification of 25
genotypically affected family members based solely on their
relationship to the index case permits an unbiased assessment of the
effect of inheritance of these mutations on clinical and biochemical
parameters. Moreover, tracing the inheritance of mutations
through the family for the first time permits unambiguous genotypic
distinction of heterozygous from wild-type homozygous individuals. The
laboratory values in patients of different genotypic classes are shown
in
Figure 3. Individuals inheriting 2 defective copies of
NCCT all had significant
hypokalemia, (mean K+ 2.8 mmol/L, range
1.9 to 3.4 mmol/L), whereas the means of both the homozygous
wild-type and heterozygous individuals were 4.3 mmol/L, with no
individual <3.5 mmol/L
(P<0.0001,
Figure 3A). Similarly, the mean serum bicarbonate levels
were also significantly higher than those of the homozygous wild-type
and heterozygous individuals
(Figure 3C).
|
In addition to these effects on K+ and bicarbonate, significant effects were also seen on Mg2+ and Ca2+ handling. Serum Mg2+ was markedly diminished among genotypically affected subjects, with a mean of 1.1 mg/dL (0.45 mmol/L, range 0.6 to 1.8 mg/dL or 0.25 to 0.74 mmol/L) compared with 1.9 mg/dL (0.78 mmol/L) in unaffected relatives (P<0.0001, Figure 3B). Patients with Gitelmans syndrome have been noted to have diminished urinary Ca2+ excretion, regardless of diet. The ratio of urinary Ca2+/creatinine was markedly diminished in Gitelmans patients compared with their unaffected relatives (P<0.0001, Figure 3D).
In the chronic state, patients 24-hour urinary Na+ and K+ levels reflect their self-selected dietary consumption. The results demonstrated a highly significant difference in urinary Na+ and K+ among the genotype classes, with genotypically affected subjects having the highest urinary Na+ (P=0.006) and K+ (P<0.0001) values (Figure 3E and 3F).
Among the genotypically affected Gitelmans patients, there was no significant difference between males and females in mean serum K+ (2.8 versus 2.8 mmol/L, respectively), bicarbonate (28 versus 28 mmol/L), Mg2+ (1.2 versus 1.1 mg/dL or 0.49 versus 0.45 mmol/L), or urinary Ca2+/creatinine ratio (0.14 versus 0.15 mmol/mmol). Among the affected patients, there were no significant correlations among these 4 laboratory values.
Effects of Mutations on Blood Pressure
None of the 26 genotypically affected subjects had a
diagnosis of hypertension, none was being treated with antihypertensive
medication, and none had a blood pressure >140/90 mm Hg. The
mean blood pressure in this group was 109/68 mm Hg for adult
males and 113/66 mm Hg for adult females.
The quantitative impact of Gitelmans mutations on blood pressure was analyzed by multiple linear regression, comparing blood pressures of relatives of contrasting NCCT genotypes. NCCT genotype, age, and gender were all significant predictors of diastolic and systolic blood pressure (Table). The effect of genotype on diastolic blood pressure was highly significant (P=0.002), with genotypically affected individuals having age- and gender-adjusted diastolic blood pressures 7.0 and 8.6 mm Hg lower than those of their heterozygous and wild-type relatives, respectively (Figure 4). The effect of genotype on systolic blood pressure was also significant and quantitatively similar (Table, P=0.038).
|
|
Effects in Heterozygous Individuals
We compared the phenotypes of heterozygous
individuals with those of their wild-type relatives. There were no
statistically significant differences in the heterozygous and the
homozygous wild-type subjects in terms of serum
K+, Mg2+,
bicarbonate, and urinary Ca2+ and
K+ excretion
(Figure 3). However, 24-hour urinary
Na+ excretion was significantly higher in
the heterozygous individuals (urinary
Na+/creatinine 20.3 versus
14.4 mmol/mmol, heterozygous versus wild-type individuals,
respectively; P=0.003). This
observation is consistent with these patients having mild salt
wasting. Although analysis of blood pressure for the entire
study population did not detect a significant difference in age- and
gender-adjusted diastolic blood pressure between
heterozygous and homozygous wild-type individuals, the higher urinary
Na+ excretion in the heterozygous group
suggests that the heterozygous individuals have self-selected a higher
Na+ intake to compensate for a mild
salt-wasting defect.
Because young individuals may have less opportunity to self-select their salt intake and may therefore have less ability to compensate for a mild defect, we tested the genotypic effect on blood pressure in children (aged <18 years). Young heterozygous individuals (n=29) had mean age and gender-adjusted diastolic blood pressure 8.7 mm Hg lower than that of homozygous wild-type relatives (n=11, P=0.004). Although there were only 2 genotypically affected children in the kindred, their mean diastolic blood pressure was 12.9 mm Hg lower than that of homozygous wild-type individuals, consistent with a stepwise effect of mutant gene dose on blood pressure in children. Together, these results provide evidence of a significant effect of the heterozygous genotype on salt homeostasis and blood pressure.
| Discussion |
|---|
|
|
|---|
Prior studies of this syndrome have largely relied on the identification of cases via abnormalities in electrolytes, potentially introducing ascertainment bias.3 4 5 7 Identification of 25 patients with 2 inherited NCCT mutations based solely on their relationship to an index case and the finding that all of these subjects have hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria demonstrate the complete penetrance of these features among such individuals. Moreover, the cosegregation of this constellation of biochemical abnormalities with mutant NCCT alleles across this extended kindred constitutes proof that the observed hypomagnesemia and hypocalciuria, findings of uncertain etiology from known physiology, are in fact attributable to inheritance at the NCCT locus, underscoring the relationship between salt reabsorption in the DCT and renal Mg2+ and Ca2+ homeostasis.
The effects on Mg2+ homeostasis are particularly striking. Renal Mg2+ reabsorption has been believed to be mediated largely through paracellular conductance in the thick ascending limb of Henle, with only a small fraction of reabsorption occurring in the DCT.11 It is consequently surprising that a defect in salt reabsorption in the DCT should result in hypomagnesemia. This observation raises the possibility that the DCT normally mediates the final fine tuning of Mg2+ homeostasis, analogous to the role played by the epithelial Na+ channel for salt homeostasis in the distal nephron. The mechanism underlying this defect is uncertain. Similarly, hypocalciuria is a consistent finding among patients with these mutations, indicating a consistent influence of salt handling in the DCT on renal Ca2+ homeostasis.
The results of investigation of this kindred provide formal demonstration that the homozygous state for Gitelmans syndrome lowers blood pressure in humans. The salt wasting of Gitelmans syndrome is relatively mild. Nonetheless, these individuals have blood pressure lower than that of their unaffected relatives. This reduction in blood pressure is highly significant and is seen in both genders. Moreover, because these subjects have self-selected a markedly higher salt diet, it is likely that their blood pressures would be even lower without this adaptation. Although thiazide diuretics have long been recognized to have blood pressurelowering effects, the present study indicates that loss of a single target, the gene product of NCCT, is sufficient to account for the blood pressurelowering effects of these agents. Moreover, these findings indicate some of the inherent limits in the use of antagonists of the NCCT gene product. For example, complete inhibition of this target can be predicted to almost invariably lead to hypomagnesemia. Therefore, these observations predict both the utility and the limits in the use of antagonists of this target.
These findings are unlikely to be unique to the kindred studied. We have investigated a cohort of 70 unrelated adult patients with Gitelmans syndrome in whom 2 mutant NCCT alleles have been identified. In this group, 83% of subjects had blood pressures that fell below the median diastolic blood pressure of the National Health and Nutrition Examination Survey (NHANES) participants of comparable age and gender (D.N. Cruz and R.P. Lifton, unpublished data, 2000), supporting the general effect of NCCT mutations in lowering blood pressure.
Previous studies have demonstrated that mutations that increase renal salt reabsorption increase blood pressure.2 The present observations formally demonstrate the opposite side of this equation, namely, that mutations that reduce renal salt reabsorption reduce blood pressure. These findings together demonstrate a strong and consistent effect of salt balance on blood pressure in humans that operates in both directions, demonstrating that alteration in salt balance represents a final common pathway for altering blood pressure in humans.
In addition, the present studies demonstrate a
significant effect of the heterozygous state, with significantly
increased dietary salt intake and, in younger individuals, lower blood
pressure. This is of relevance because
1% of the population is
likely to be heterozygous for mutations in this gene. These
observations raise the question of whether the heterozygous state might
underlie additional phenotypes. For example,
diuretic-induced hypokalemia is a relatively common
complication of loop diuretics; it is possible that
NCCT heterozygous individuals
may be more susceptible to this complication.
With regard to observational studies of the relationship between salt and blood pressure, it is worth noting that although primary salt wasting leads to lower blood pressure in Gitelmans syndrome, in these patients there is actually an inverse relationship between dietary salt and blood pressure that is due to compensatory self selection of a high salt diet. Complexities such as these underscore the difficulties in interpreting observational studies of the saltblood pressure relationship that do not investigate the underlying physiology of individual subjects. These observations raise the question of whether identification of individuals with very high salt intake but very low blood pressure might identify other subsets of patients with impaired renal salt reabsorption.
The demonstration of a consistent relationship between altered renal salt handling and blood pressure variation in humans identifies one of the final common pathways for altered blood pressure. These findings are beginning to put a molecular face on the physiological studies of Guyton,12 who demonstrated the requirement for an active role of the kidney in the development of hypertension. These observations in rare mendelian disorders raise the possibility that common variants in genes that mediate or regulate salt homeostasis in humans might underlie blood pressure variation in the general population. Moreover, they identify targets for the development of improved antihypertensive agents that may more closely address the abnormal physiology contributing to disease pathogenesis.
| Acknowledgments |
|---|
Received September 27, 2000; first decision October 19, 2000; accepted November 20, 2000.
| References |
|---|
|
|
|---|
2. Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996;272:676680.[Abstract]
3. Bettinelli A, Vezzoli G, Colussi G, Bianchetti MG, Sereni F, Casari G. Genotype-phenotype correlations in normotensive patients with primary renal tubular hypokalemic metabolic alkalosis. J Nephrol. 1998;11:6169.[Medline] [Order article via Infotrieve]
4. De Heide L, Birkenhager J. Bartters syndrome, hypomagnesemia and chondrocalcinosis. Neth J Med. 1991;39:148152.[Medline] [Order article via Infotrieve]
5. Puschett J, Greenberg A, Mitro R, Piraino B, Wallia R. Variant of Bartters syndrome with a distal tubular rather than loop of Henle defect. Nephron. 1988;50:205211.[Medline] [Order article via Infotrieve]
6. Simon DB, Lifton RP. Ion transporter mutations in Gitelmans and Bartters syndromes. Curr Opin Nephrol Hypertens. 1998;7:4347.[Medline] [Order article via Infotrieve]
7. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, et al. Gitelmans variant of Bartters syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996;12:2430.[Medline] [Order article via Infotrieve]
8.
Bell G, Karam J,
Rutter W. Polymorphic DNA region adjacent to the 5' end of the
human insulin gene. Proc Natl Acad Sci
U S A. 1981;78:57595763.
9.
Gamba G, Saltzberg
SN, Lombardi M, Miyanoshita A, Lytton J, Hediger MA, Brenner BM, Hebert
SC. Primary structure and functional expression of a cDNA encoding the
thiazide-sensitive, electroneutral sodium-chloride cotransporter.
Proc Natl Acad Sci
U S A. 1993;90:27492753.
10.
Gamba G,
Miyanoshita A, Lombardi M, Lytton J, Lee WS, Hediger MA, Hebert SC.
Molecular cloning, primary structure, and characterization of two
members of the mammalian electroneutral sodium-(potassium)-chloride
cotransporter family expressed in the kidney.
J Biol Chem. 1994;269:1771317722.
11.
Simon DB, Lu Y,
Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A,
Colussi G, Rodriguez-Soriano J, et al. Paracellin-1, a renal tight
junction protein required for paracellular
Mg2+ resorption.
Science. 1999;285:103106.
12.
Guyton AC. Blood
pressure control: special role of the kidneys and body fluids.
Science. 1991;252:18131816.
This article has been cited by other articles:
![]() |
M. Moser and P. U. Feig Fifty Years of Thiazide Diuretic Therapy for Hypertension Arch Intern Med, November 9, 2009; 169(20): 1851 - 1856. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Ellison and J. Loffing Thiazide Effects and Adverse Effects: Insights From Molecular Genetics Hypertension, August 1, 2009; 54(2): 196 - 202. [Full Text] [PDF] |
||||
![]() |
D. B. Mount Splicing a Kinase and the Regulation of Salt Transport J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1166 - 1168. [Full Text] [PDF] |
||||
![]() |
M. Roser, N. Eibl, B. Eisenhaber, J. Seringer, M. Nagel, S. Nagorka, F. C. Luft, U. Frei, and M. Gollasch Gitelman Syndrome Hypertension, June 1, 2009; 53(6): 893 - 897. [Full Text] [PDF] |
||||
![]() |
U. I. Scholl, M. Choi, T. Liu, V. T. Ramaekers, M. G. Hausler, J. Grimmer, S. W. Tobe, A. Farhi, C. Nelson-Williams, and R. P. Lifton Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10 PNAS, April 7, 2009; 106(14): 5842 - 5847. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Hsu, S.-S. Yang, N.-F. Chu, H.-K. Sytwu, C.-J. Cheng, and S.-H. Lin Heterozygous mutations of the sodium chloride cotransporter in Chinese children: prevalence and association with blood pressure Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1170 - 1175. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Rossier and L. Schild Epithelial Sodium Channel: Mendelian Versus Essential Hypertension Hypertension, October 1, 2008; 52(4): 595 - 600. [Full Text] [PDF] |
||||
![]() |
C. Fava, M. Montagnana, L. Rosberg, P. Burri, P. Almgren, A. Jonsson, P. Wanby, G. Lippi, P. Minuz, L.U. Hulthen, et al. Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure Hum. Mol. Genet., February 1, 2008; 17(3): 413 - 418. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Geerling and A. D. Loewy Central regulation of sodium appetite Exp Physiol, February 1, 2008; 93(2): 177 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J Brown Renin: friend or foe? Heart, September 1, 2007; 93(9): 1026 - 1033. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Schmidlin, A. Forman Anthony Sebastian, and R. C. Morris Jr What Initiates the Pressor Effect of Salt in Salt-Sensitive Humans?: Observations in Normotensive Blacks Hypertension, May 1, 2007; 49(5): 1032 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Riveira-Munoz, Q. Chang, N. Godefroid, J. G. Hoenderop, R. J. Bindels, K. Dahan, O. Devuyst, and for the Belgian Network for the Study of Gitelman Transcriptional and Functional Analyses of SLC12A3 Mutations: New Clues for the Pathogenesis of Gitelman Syndrome J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1271 - 1283. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Iwai, K. Kajimoto, H. Tomoike, and N. Takashima Polymorphism of CYP11B2 Determines Salt Sensitivity in Japanese Hypertension, April 1, 2007; 49(4): 825 - 831. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Golbang, G. Cope, A. Hamad, M. Murthy, C.-H. Liu, A. W. Cuthbert, and K. M. O'Shaughnessy Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1369 - F1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Iwai, K. Kajimoto, Y. Kokubo, and H. Tomoike Extensive Genetic Analysis of 10 Candidate Genes for Hypertension in Japanese Hypertension, November 1, 2006; 48(5): 901 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Sandberg, A. B. Maunsbach, and A. A. McDonough Redistribution of distal tubule Na+-Cl- cotransporter (NCC) in response to a high-salt diet Am J Physiol Renal Physiol, August 1, 2006; 291(2): F503 - F508. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Alderman Evidence relating dietary sodium to cardiovascular disease. J. Am. Coll. Nutr., June 1, 2006; 25(3 Suppl): 256S - 261S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gamba Molecular Physiology and Pathophysiology of Electroneutral Cation-Chloride Cotransporters Physiol Rev, April 1, 2005; 85(2): 423 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Meneton, X. Jeunemaitre, H. E. de Wardener, and G. A. Macgregor Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases Physiol Rev, April 1, 2005; 85(2): 679 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bianchi, P. Ferrari, and J. A. Staessen Adducin Polymorphism: Detection and Impact on Hypertension and Related Disorders Hypertension, March 1, 2005; 45(3): 331 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Francis, J. Zhang, A. Farhi, H. Carey, and D. S. Geller A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2893 - 2895. [Full Text] [PDF] |
||||
![]() |
J. Loffing, V. Vallon, D. Loffing-Cueni, F. Aregger, K. Richter, L. Pietri, M. Bloch-Faure, J. G.J. Hoenderop, G. E. Shull, P. Meneton, et al. Altered Renal Distal Tubule Structure and Renal Na+ and Ca2+ Handling in a Mouse Model for Gitelman's Syndrome J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2276 - 2288. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sabath, P. Meade, J. Berkman, P. d. l. Heros, E. Moreno, N. A. Bobadilla, N. Vazquez, D. H. Ellison, and G. Gamba Pathophysiology of functional mutations of the thiazide-sensitive Na-Cl cotransporter in Gitelman disease Am J Physiol Renal Physiol, August 1, 2004; 287(2): F195 - F203. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Alderman Dietary Sodium and Cardiovascular Health in Hypertensive Patients: The Case against Universal Sodium Restriction J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S47 - 50. [Abstract] [Full Text] |
||||
![]() |
P. Strazzullo, F. Galletti, and G. Barba Altered Renal Handling of Sodium in Human Hypertension: Short Review of the Evidence Hypertension, May 1, 2003; 41(5): 1000 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Ellison The Thiazide-Sensitive Na-Cl Cotransporter and Human Disease: Reemergence of an Old Player J. Am. Soc. Nephrol., February 1, 2003; 14(2): 538 - 540. [Full Text] [PDF] |
||||
![]() |
H. Mayan, I. Vered, M. Mouallem, M. Tzadok-Witkon, R. Pauzner, and Z. Farfel Pseudohypoaldosteronism Type II: Marked Sensitivity to Thiazides, Hypercalciuria, Normomagnesemia, and Low Bone Mineral Density J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3248 - 3254. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.P. LIFTON, F.H. WILSON, K.A. CHOATE, and D.S. GELLER Salt and Blood Pressure: New Insight from Human Genetic Studies Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 445 - 450. [Abstract] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |